Acute Respiratory Distress Syndrome (ARDS) remains a critical challenge in medicine, persistently linked to mortality rates exceeding 30% despite extensive research over the years. The lack of effective drug treatments means that care for ARDS patients relies heavily on supportive interventions, with lung-protective ventilation being a core strategy.

To optimize this crucial ventilation strategy, neuromuscular blocking agents (NMBAs) are utilized. The primary goal of NMBAs is to eliminate the patient’s spontaneous breathing efforts, which in turn reduces patient-ventilator asynchrony.

By doing this, NMBAs prevent the generation of damagingly high transpulmonary pressures, which could exacerbate self-inflicted lung injury (SILI), and ensure the precise and consistent delivery of necessary low tidal volume ventilation.

This supportive pharmacological approach is vital for facilitating a less injurious environment for the lungs during mechanical ventilation.

Read More